Which clinical programs advanced to next‑phase trials and what are their expected timelines?

Answer

The brief news summary you provided does not contain the details needed to identify:

1. Which specific clinical programs at AnaptysBio have been advanced to the next phase of their trials, and
   
2. The expected timelines for those next‑phase activities (e.g., start of Phase II/III, anticipated enrollment periods, or projected read‑out dates).

Typically, a company’s quarterly earnings release that includes a “business update” will list the programs that have moved forward (e.g., from Phase 1 to Phase 2, or from Phase 2 to Phase 3) and give an outlook such as “Phase 2 enrollment is expected to begin in Q4 2025” or “Phase 3 read‑out is projected for mid‑2026.” However, those specifics are not present in the excerpt you shared.

What to do next

• Locate the full press release (often posted on the company’s investor‑relations website or on GlobeNewswire). The complete document will contain a “Business Update” section that enumerates the programs advancing and their anticipated timelines.
• Check the “Investor Presentation” that often accompanies earnings releases; slide decks usually include a pipeline slide with phase‑by‑phase updates and target dates.
• Review the SEC filing (e.g., Form 8‑K) that the press release is linked to, as it often repeats the same forward‑looking statements.

If you can provide the full text (or a more detailed excerpt) of the AnaptysBio Q2 2025 results release, I’ll be able to extract the exact program names and timeline expectations for you.